argenxARGX
ARGX
About: Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Employees: 1,639
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
207% more first-time investments, than exits
New positions opened: 83 | Existing positions closed: 27
84% more call options, than puts
Call options by funds: $319M | Put options by funds: $174M
13% more funds holding
Funds holding: 391 [Q4 2024] → 440 (+49) [Q1 2025]
5% more repeat investments, than reductions
Existing positions increased: 155 | Existing positions reduced: 148
0% more funds holding in top 10
Funds holding in top 10: 18 [Q4 2024] → 18 (+0) [Q1 2025]
1.62% less ownership
Funds ownership: 56.52% [Q4 2024] → 54.89% (-1.62%) [Q1 2025]
6% less capital invested
Capital invested by funds: $21B [Q4 2024] → $19.7B (-$1.25B) [Q1 2025]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$680
18%
upside
Avg. target
$782
35%
upside
High target
$1,065
84%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Wedbush David Nierengarten | 24%upside $715 | Outperform Reiterated | 11 Jun 2025 |
HC Wainwright & Co. Douglas Tsao | 25%upside $720 | Buy Reiterated | 11 Jun 2025 |
Baird Joel Beatty | 18%upside $680 | Outperform Upgraded | 13 May 2025 |
Oppenheimer Leland Gershell | 23%upside $708 | Outperform Maintained | 9 May 2025 |
Guggenheim Yatin Suneja | 84%upside $1,065 | Buy Maintained | 9 May 2025 |
Financial journalist opinion
Based on 4 articles about ARGX published over the past 30 days
Neutral
GlobeNewsWire
4 days ago
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease
ALKIVIA data demonstrate significant improvement in muscle strength and physical function in myositis patients treated with efgartigimod RHO data show efgartigimod achieved sustained reduction in autoantibodies and improved functional outcomes in patients with Sjogren's disease; program granted U.S. FDA Fast Track designation argenx committed to new therapeutic areas in rheumatology with ongoing Phase 3 studies in myositis (ALKIVIA) and Sjogren's disease (UNITY) June 11, 2025, 12:01 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the presentation of positive results from Phase 2 studies evaluating VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) in Sjogren's disease (SjD) and idiopathic inflammatory myopathies (IIM or myositis) at the European Congress of Rheumatology, EULAR 2025, from June 11 – 14 in Barcelona, Spain. argenx also announced that the U.S. Food and Drug Administration (FDA) has granted efgartigimod Fast Track designation (FTD) for the treatment of primary Sjogren's disease.
Neutral
GlobeNewsWire
1 week ago
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
June 3, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karl Gubitz, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 8:40 AM ET in Miami, FL.
Neutral
GlobeNewsWire
2 weeks ago
argenx Announces Results of Annual General Meeting of Shareholders
May 28, 2025 – 10:01 PM C ET
Neutral
Zacks Investment Research
3 weeks ago
EXEL vs. ARGX: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
Positive
Zacks Investment Research
1 month ago
Argenx (ARGX) Upgraded to Buy: Here's Why
Argenx (ARGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Seeking Alpha
1 month ago
Argenx Q1 Earnings: Less Than Perfect Report Gets Punished
Shares of argenx declined yesterday as Vyvgart missed investors' expectations. Vyvgart saw the usual negative seasonal headwinds in the U.S. in the first quarter that were further exacerbated by the Medicare redesign. Underlying demand was strong across the globe, and Vyvgart looks well positioned for continued growth, which should be helped by the approval of the PFS and international indication expansion.
Neutral
Seeking Alpha
1 month ago
argenx SE (ARGX) Q1 2025 Earnings Call Transcript
argenx SE (NASDAQ:ARGX ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Karen Massey - Chief Operating Officer Conference Call Participants Tazeen Ahmad - Bank of America Alex Thompson - Stifel Vikram Purohit - Morgan Stanley Rajan Sharma - Goldman Sachs James Gordon - JPMorgan Derek Archila - Wells Fargo Yaron Werber - TD Cowen Victor Floch - BNP Paribas Nat Charoensook - Leerink Partners Amy Li - Jefferies Charles Pitman-King - Barclays Myles Minter - William Blair Suzanne van Voorthuizen - Kempen Yatin Suneja - Guggenheim Andy Chen - Wolfe Research David Nierengarten - Wedbush Securities Gavin Clark-Gartner - Evercore ISI Samantha Semenkow - Citi Leland Gershell - Oppenheimer Joel Beatty - Baird Xian Deng - UBS Operator Good morning. My name is Rob, and I will be your conference operator today.
Positive
Investors Business Daily
1 month ago
Argenx Beats Sales Expectations — But Not By Enough — And Shares Tumble
Argenx stock tumbled Thursday after its drug, Vyvgart, beat sales expectations. But the beat wasn't strong enough for investors.
Neutral
GlobeNewsWire
1 month ago
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
$790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opinion for VYVGART-SC (vial and pre-filled syringe) in EU Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 8, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2025 financial results and provided a business update. “We continue to execute on our bold innovation agenda, guided by our ‘Vision 2030' to reach 50,000 patients across 10 labeled indications,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
Neutral
Zacks Investment Research
1 month ago
AZN or ARGX: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Astrazeneca (AZN) or argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
Charts implemented using Lightweight Charts™